Phage Display of the Serpin Alpha-1 Proteinase Inhibitor Randomized at Consecutive Residues in the Reactive Centre Loop and Biopanned with or without Thrombin

In spite of the power of phage display technology to identify variant proteins with novel properties in large libraries, it has only been previously applied to one member of the serpin superfamily. Here we describe phage display of human alpha-1 proteinase inhibitor (API) in a T7 bacteriophage system. API M358R fused to the C-terminus of T7 capsid protein 10B was directly shown to form denaturation-resistant complexes with thrombin by electrophoresis and immunoblotting following exposure of intact phages to thrombin. We therefore developed a biopanning protocol in which thrombin-reactive phages were selected using biotinylated anti-thrombin antibodies and streptavidin-coated magnetic beads. A library consisting of displayed API randomized at residues 357 and 358 (P2–P1) yielded predominantly Pro-Arg at these positions after five rounds of thrombin selection; in contrast the same degree of mock selection yielded only non-functional variants. A more diverse library of API M358R randomized at residues 352–356 (P7–P3) was also probed, yielding numerous variants fitting a loose consensus of DLTVS as judged by sequencing of the inserts of plaque-purified phages. The thrombin-selected sequences were transferred en masse into bacterial expression plasmids, and lysates from individual colonies were screening for API-thrombin complexing. The most active candidates from this sixth round of screening contained DITMA and AAFVS at P7–P3 and inhibited thrombin 2.1-fold more rapidly than API M358R with no change in reaction stoichiometry. Deep sequencing using the Ion Torrent platform confirmed that over 800 sequences were significantly enriched in the thrombin-panned versus naïve phage display library, including some detected using the combined phage display/bacterial lysate screening approach. Our results show that API joins Plasminogen Activator Inhibitor-1 (PAI-1) as a serpin amenable to phage display and suggest the utility of this approach for the selection of “designer serpins” with novel reactivity and/or specificity.

[1]  B. Cooperman,et al.  Conversion of alpha 1-antichymotrypsin into a human neutrophil elastase inhibitor: demonstration of variants with different association rate constants, stoichiometries of inhibition, and complex stabilities. , 1994, Biochemistry.

[2]  J. Travis,et al.  Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. , 1980, The Journal of biological chemistry.

[3]  D. Tollefsen,et al.  Ligand binding to thrombin exosite II induces dissociation of the thrombin-heparin cofactor II(L444R) complex. , 1998, Biochemistry.

[4]  V. Bhakta,et al.  The transferable tail: fusion of the N-terminal acidic extension of heparin cofactor II to alpha1-proteinase inhibitor M358R specifically increases the rate of thrombin inhibition. , 2006, Biochemistry.

[5]  Francesco Leonetti,et al.  Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin , 2000, Nature Biotechnology.

[6]  P. Gettins.  Serpin structure, mechanism, and function. , 2002, Chemical reviews.

[7]  V. Bhakta,et al.  Expression screening of bacterial libraries of recombinant alpha-1 proteinase inhibitor variants for candidates with thrombin inhibitory capacity. , 2013, Journal of biotechnology.

[8]  R. Carrell,et al.  Effects of mutations in the hinge region of serpins. , 1993, Biochemistry.

[9]  M. O. Dayhoff,et al.  A surprising new protein superfamily containing ovalbumin, antithrombin-III, and alpha 1-proteinase inhibitor. , 1980, Biochemical and biophysical research communications.

[10]  P. Patston,et al.  Influence of the P5 Residue on α1-Proteinase Inhibitor Mechanism* , 1998, The Journal of Biological Chemistry.

[11]  V. Bhakta,et al.  The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of α1-proteinase inhibitor M358R for thrombin , 2007, Thrombosis and Haemostasis.

[12]  L. Hellman,et al.  The Extended Cleavage Specificity of Human Thrombin , 2012, PloS one.

[13]  J H Lewis,et al.  Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. , 1983, The New England journal of medicine.

[14]  D. Lawrence,et al.  Molecular evolution of plasminogen activator inhibitor‐1 functional stability. , 1995, The EMBO journal.

[15]  D. Tollefsen,et al.  Heparin cofactor II. , 1997, Advances in experimental medicine and biology.

[16]  F. Church,et al.  Heparin Promotes Proteolytic Inactivation by Thrombin of a Reactive Site Mutant (L444R) of Recombinant Heparin Cofactor II* , 1997, The Journal of Biological Chemistry.

[17]  V. Bhakta,et al.  Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition. , 2004, Biochemistry.

[18]  Ratmir Derda,et al.  Deep sequencing analysis of phage libraries using Illumina platform. , 2012, Methods.

[19]  James C Whisstock,et al.  Serpins Flex Their Muscle , 2010, The Journal of Biological Chemistry.

[20]  B. L. Le Bonniec,et al.  Intrinsic specificity of the reactive site loop of alpha1-antitrypsin, alpha1-antichymotrypsin, antithrombin III, and protease nexin I. , 1997, The Journal of biological chemistry.

[21]  J. Abrahams,et al.  Wild-type alpha 1-antitrypsin is in the canonical inhibitory conformation. , 1998, Journal of molecular biology.

[22]  R. Read,et al.  Structure of a serpin–protease complex shows inhibition by deformation , 2000, Nature.

[23]  J. Whisstock,et al.  The role of strand 1 of the C β‐sheet in the structure and function of α1‐antitrypsin , 2001 .

[24]  J H Lewis,et al.  Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf. , 1986, The Journal of clinical investigation.

[25]  P. Stein,et al.  What do dysfunctional serpins tell us about molecular mobility and disease? , 1995, Nature Structural Biology.

[26]  R. Bischoff,et al.  Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358. , 1990, The Journal of biological chemistry.

[27]  R. Leduc,et al.  The Contribution of Arginine Residues within the P6–P1 Region of α1-Antitrypsin to Its Reaction with Furin* , 2001, The Journal of Biological Chemistry.

[28]  J. Whisstock,et al.  An overview of the serpin superfamily , 2006, Genome Biology.

[29]  D. Goodsell,et al.  Visualization of macromolecular structures , 2010, Nature Methods.

[30]  C. Barbas,et al.  Functional display of human plasminogen-activator inhibitor 1 (PAI-1) on phages: novel perspectives for structure-function analysis by error-prone DNA synthesis. , 1993, Gene.

[31]  D. Tollefsen,et al.  Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. , 1982, The Journal of biological chemistry.

[32]  R. Carrell,et al.  Development of a Novel Recombinant Serpin with Potential Antithrombotic Properties (*) , 1995, The Journal of Biological Chemistry.

[33]  Sindy K. Y. Tang,et al.  Prospective identification of parasitic sequences in phage display screens , 2013, Nucleic acids research.

[34]  T. Bratkovič,et al.  Progress in phage display: evolution of the technique and its applications , 2010, Cellular and Molecular Life Sciences.

[35]  P. Liaw,et al.  Retention of thrombin inhibitory activity by recombinant serpins expressed as integral membrane proteins tethered to the surface of mammalian cells , 2011, Journal of thrombosis and haemostasis : JTH.

[36]  R. Pike,et al.  Evolution of Serpin Specificity: Cooperative Interactions in the Reactive-Site Loop Sequence of Antithrombin Specifically Restrict the Inhibition of Activated Protein C , 2000, Journal of Molecular Evolution.

[37]  P. Gettins,et al.  Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 A and full insertion of the reactive center loop into beta-sheet A. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Anil K. Saxena,et al.  Profiling the Structural Determinants for the Selectivity of Representative Factor-Xa and Thrombin Inhibitors Using Combined Ligand-Based and Structure-Based Approaches , 2011, J. Chem. Inf. Model..

[39]  R. Carrell,et al.  Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. , 1989, Biochemistry.

[40]  R. Colman,et al.  Recombinant Antitrypsin Pittsburgh Undergoes Proteolytic Cleavage during E. coli Sepsis and Fails to Prevent the Associated Coagulopathy in a Primate Model , 1998, Thrombosis and Haemostasis.

[41]  P. C. Hopkins,et al.  The contribution of the conserved hinge region residues of alpha1-antitrypsin to its reaction with elastase. , 1995, Biochemistry.

[42]  R. Leduc,et al.  Stability of mutant serpin/furin complexes: Dependence on pH and regulation at the deacylation step , 2005, Protein science : a publication of the Protein Society.

[43]  Borut Strukelj,et al.  Phage Display: Selecting Straws Instead of a Needle from a Haystack , 2011, Molecules.

[44]  Piotr J. Balwierz,et al.  Methods for analyzing deep sequencing expression data: constructing the human and mouse promoterome with deepCAGE data , 2009, Genome Biology.

[45]  A. V. van Zonneveld,et al.  Selective Screening of a Large Phage Display Library of Plasminogen Activator Inhibitor 1 Mutants to Localize Interaction Sites with Either Thrombin or the Variable Region 1 of Tissue-type Plasminogen Activator (*) , 1996, The Journal of Biological Chemistry.

[46]  V. Bhakta,et al.  Investigating serpin-enzyme complex formation and stability via single and multiple residue reactive centre loop substitutions in heparin cofactor II. , 2006, Thrombosis research.

[47]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.

[48]  P. C. Hopkins,et al.  Role of the P2 residue in determining the specificity of serpins. , 1996, Biochemistry.

[49]  J. Huntington.  Serpin structure, function and dysfunction , 2011, Journal of thrombosis and haemostasis : JTH.

[50]  J. Dobó,et al.  Active Site Distortion Is Sufficient for Proteinase Inhibition by Serpins , 2006, Journal of Biological Chemistry.

[51]  V. V. Van Deerlin,et al.  Heparin Facilitates Dissociation of Complexes between Thrombin and a Reactive Site Mutant (L444R) of Heparin Cofactor II* , 1997, The Journal of Biological Chemistry.

[52]  R. Read,et al.  Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries. , 2001, Journal of molecular biology.

[53]  Sindy K. Y. Tang,et al.  Diversity of Phage-Displayed Libraries of Peptides during Panning and Amplification , 2011, Molecules.

[54]  I. Lasters,et al.  High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I). , 2000, Journal of molecular biology.

[55]  H. Chapman,et al.  Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysis. , 1998, Biochemistry.

[56]  Philip Hugenholtz,et al.  Shining a Light on Dark Sequencing: Characterising Errors in Ion Torrent PGM Data , 2013, PLoS Comput. Biol..

[57]  V. Bhakta,et al.  Reduction of thrombus size in murine models of thrombosis following administration of recombinant α1-proteinase inhibitor mutant proteins , 2012, Thrombosis and Haemostasis.

[58]  B. L. Le Bonniec,et al.  Intrinsic Specificity of the Reactive Site Loop of α1-Antitrypsin, α1-Antichymotrypsin, Antithrombin III, and Protease Nexin I* , 1997, The Journal of Biological Chemistry.

[59]  H. Swerdlow,et al.  A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers , 2012, BMC Genomics.

[60]  M. Stephens,et al.  RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. , 2008, Genome research.

[61]  M. A. Cunningham,et al.  Altering Heparin Cofactor II at VAL439 (P6) either Impairs Inhibition of Thrombin or Confers Elastase Resistance , 2002, Thrombosis and Haemostasis.